<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37607780</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000910</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2023-000910</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To characterise the safety and efficacy of anifrolumab in active lupus nephritis (LN) through year 2 of the phase II randomised, double-blind Treatment of Uncontrolled Lupus via the Interferon Pathway (TULIP)-LN trial (NCT02547922) of 2 anifrolumab dosing regimens versus placebo.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients received intravenous anifrolumab 900 mg for the first 3 doses followed by 300 mg anifrolumab (intensified regimen (IR)), 300 mg anifrolumab (basic regimen (BR)) or placebo every 4 weeks throughout. To continue into Year 2, patients must have achieved at least partial renal response and a glucocorticoid tapering target.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 147 randomised patients, 101 completed Year 1 study treatment; of these, 75 (74%) continued into Year 2 (anifrolumab IR: n=29, BR: n=23 and placebo: n=23). During Year 2, 72% of patients reported &#x2265;1 adverse event (AE); serious AEs were reported in 6.9%, 8.7% and 8.7% of patients (anifrolumab IR, BR and placebo, respectively); 3 patients discontinued treatment due to an AE (anifrolumab IR: n=2&#x2009;and placebo: n=1) and herpes zoster was reported in 2 patients (anifrolumab IR: n=1&#x2009;and BR: n=1). The study was ongoing at the start of the pandemic, but no COVID-19 cases were reported. Of the 145 patients receiving treatment, more patients on the IR attained complete renal response at Week 104 compared with those on BR or placebo (27.3% vs 18.6% and 17.8%) and simultaneously achieved sustained glucocorticoid tapering (IR: 25.0%; BR: 18.6% and placebo: 17.8%). The improvements in estimated glomerular filtration rate were numerically larger in both anifrolumab groups versus placebo.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The safety and tolerability profile through Year 2 of TULIP-LN was generally consistent with Year 1, with promising efficacy results for the anifrolumab IR regimen. Collectively, the results support further investigation of an anifrolumab intensified dosing regimen in larger populations of patients with active proliferative LN.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">NCT02547922.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jayne</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-1712-0637</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rovin</LastName><ForeName>Brad</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-5639-0210</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine-Nephrology, The Ohio State University, Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mysler</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-8993-0313</Identifier><AffiliationInfo><Affiliation>Rheumatology, Organizacion Medica de Investigacion SA, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furie</LastName><ForeName>Richard</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-6712-1585</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houssiau</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-1451-083X</Identifier><AffiliationInfo><Affiliation>Rheumatology Department, Cliniques universitaires Saint-Luc, Institut de Recherche Exp&#xe9;rimentale et Clinique, Universite catholique de Louvain, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trasieva</LastName><ForeName>Teodora</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>BioPharmaceuticals R&amp;D, AstraZeneca, Goteborg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knagenhjelm</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>BioPharmaceuticals R&amp;D, AstraZeneca, Goteborg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwetje</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Weifeng</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tummala</LastName><ForeName>Raj</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindholm</LastName><ForeName>Catharina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>BioPharmaceuticals R&amp;D, AstraZeneca, Goteborg, Sweden Catharina.Lindholm@astrazeneca.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02547922</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>38RL9AE51Q</RegistryNumber><NameOfSubstance UI="C582345">anifrolumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">autoimmune diseases</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">therapeutics</Keyword></KeywordList><CoiStatement>Competing interests: DJ has received consulting fees from Boehringer Ingelheim, Chemocentryx, CSL Vifor, Novartis, Roche and Takeda; has received honoraria from CSL Vifor and GSK; has received payment for participating in Data Safety Monitoring or Advisory Boards for Chinook, GSK and Takeda and has stock or stock options in Aurinia. BR has received consulting fees from Aurinia, Alexion, AstraZeneca, Biocryst, Biogen, BMS, Calliditas, Chemocentryx, Corrona, EMD Serono, Exagen, Galapagos, Genentech-Roche, GSK, Janssen, Kezar, Lilly, MorphoSys, Novartis, Omeros, Otsuka, Pfizer, Travere and University of Minnesota; has received speaker support from the American Society of Nephrology and the International Society of Nephrology and has a leadership or fiduciary role in the Lupus Foundation of America and KDIGO Glomerulonephritis Guideline group. EM has received grants or contracts from AbbVie, AstraZeneca, BMS, Janssen, Lilly, Novartis, Pfizer and Roche; has received consulting fees from AbbVie, AstraZeneca, GSK, Janssen, Lilly and Pfizer; has received honoraria from AbbVie, Amgen, AstraZeneca, GSK, Janssen, Lilly, Pfizer and Sanofi; has received payment for expert testimony from AbbVie and has received support for attending meetings and/or travel from AbbVie and Pfizer. RF has received consulting fees, payment or honoraria for speaking, support for attending meetings from and payment for participating in a Data Safety Monitoring or Advisory Board for AstraZeneca. FH has received grants or contracts from GSK and consulting fees from IDORSIA. RT is an employee of AstraZeneca. TT, JK, ES, WT and CL are employees of AstraZeneca and own stock or stock options.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>22</Day><Hour>20</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37607780</ArticleId><ArticleId IdType="pmc">PMC10445374</ArticleId><ArticleId IdType="doi">10.1136/lupus-2023-000910</ArticleId><ArticleId IdType="pii">10/2/e000910</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Maroz N, Segal MS. Lupus nephritis and end-stage kidney disease. Am J Med Sci 2013;346:319&#x2013;23. 10.1097/MAJ.0b013e31827f4ee3</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAJ.0b013e31827f4ee3</ArticleId><ArticleId IdType="pubmed">23370533</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Ren Y, Chang J, et al. . A systematic review and meta-analysis of prevalence of biopsy-proven lupus nephritis. Arch Rheumatol 2018;33:17&#x2013;25. 10.5606/ArchRheumatol.2017.6127</Citation><ArticleIdList><ArticleId IdType="doi">10.5606/ArchRheumatol.2017.6127</ArticleId><ArticleId IdType="pmc">PMC5864167</ArticleId><ArticleId IdType="pubmed">29900975</ArticleId></ArticleIdList></Reference><Reference><Citation>Narain S, Berman N, Furie R. Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis. Curr Opin Rheumatol 2020;32:609&#x2013;16. 10.1097/BOR.0000000000000754</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000754</ArticleId><ArticleId IdType="pubmed">33002950</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Cheema K, et al. . 2019 Update of the joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020;79:713&#x2013;23. 10.1136/annrheumdis-2020-216924</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-216924</ArticleId><ArticleId IdType="pubmed">32220834</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte A, Danza A, Ruiz-Irastorza G. Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. Curr Opin Rheumatol 2018;30:482&#x2013;9. 10.1097/BOR.0000000000000527</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000527</ArticleId><ArticleId IdType="pubmed">29870497</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman MB. FDA approves belimumab &amp; voclosporin for lupus nephritis. Available: https://www.the-rheumatologist.org/article/fda-approves-belimumab-voclosporin-for-lupus-nephritis/ [Accessed 08 May 2022].</Citation></Reference><Reference><Citation>Rovin BH, Teng YKO, Ginzler EM, et al. . Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2021;397:2070&#x2013;80. 10.1016/S0140-6736(21)00578-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00578-X</ArticleId><ArticleId IdType="pubmed">33971155</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Rovin BH, Houssiau F, et al. . Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 2020;383:1117&#x2013;28. 10.1056/NEJMoa2001180</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001180</ArticleId><ArticleId IdType="pubmed">32937045</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales E, Galindo M, Trujillo H, et al. . Update on lupus nephritis: looking for a new vision. Nephron 2021;145:1&#x2013;13. 10.1159/000511268</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000511268</ArticleId><ArticleId IdType="pubmed">33147587</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Khamashta M, Merrill JT, et al. . Anifrolumab, an anti-interferon-&#x3b1; receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol 2017;69:376&#x2013;86. 10.1002/art.39962</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39962</ArticleId><ArticleId IdType="pmc">PMC5299497</ArticleId><ArticleId IdType="pubmed">28130918</ArticleId></ArticleIdList></Reference><Reference><Citation>AstraZeneca . Saphnelo (anifrolumab) approved in the US for moderate to severe systemic lupus erythematosus [press release]. Available: https://www.astrazeneca.com/media-centre/press-releases/2021/saphnelo-approved-in-the-us-for-sle.html [Accessed 11 Jan 2022].</Citation></Reference><Reference><Citation>AstraZeneca . Saphnelo approved in the EU for the treatment of moderate to severe systemic lupus erythematosus. Available: https://www.astrazeneca.com/media-centre/press-releases/2022/saphnelo-approved-in-eu-for-sle.html [Accessed 08 Mar 2022].</Citation></Reference><Reference><Citation>AstraZeneca . Saphnelo approved in Japan for systemic lupus erythematosus [press release]. Available: https://www.astrazeneca.com/media-centre/press-releases/2021/saphnelo-approved-in-japan-for-sle.html [Accessed 11 Jan 2022].</Citation></Reference><Reference><Citation>AstraZeneca . Saphnelo prescribing information. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761123s000lbl.pdf [Accessed 17 Apr 2022].</Citation></Reference><Reference><Citation>Morand EF, Furie R, Tanaka Y, et al. . Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 2020;382:211&#x2013;21. 10.1056/NEJMoa1912196</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie RA, Morand EF, Bruce IN, et al. . Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol 2019;1:e208&#x2013;19. 10.1016/S2665-9913(19)30076-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(19)30076-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Funabiki M, Kato H, Miyachi Y, et al. . Autoimmune disorders associated with gain of function of the intracellular sensor MDA5. Immunity 2014;40:199&#x2013;212. 10.1016/j.immuni.2013.12.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2013.12.014</ArticleId><ArticleId IdType="pubmed">24530055</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng X, Wu H, Grossman JM, et al. . Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:2951&#x2013;62. 10.1002/art.22044</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22044</ArticleId><ArticleId IdType="pubmed">16947629</ArticleId></ArticleIdList></Reference><Reference><Citation>Der E, Suryawanshi H, Morozov P, et al. . Author correction: tubular cell and Keratinocyte single-cell Transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat Immunol 2019;20:1556. 10.1038/s41590-019-0529-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-019-0529-4</ArticleId><ArticleId IdType="pmc">PMC9667864</ArticleId><ArticleId IdType="pubmed">31605099</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayne D, Rovin B, Mysler EF, et al. . Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis 2022;81:496&#x2013;506. 10.1136/annrheumdis-2021-221478</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221478</ArticleId><ArticleId IdType="pmc">PMC8921596</ArticleId><ArticleId IdType="pubmed">35144924</ArticleId></ArticleIdList></Reference><Reference><Citation>Weening JJ, D&#x2019;Agati VD, Schwartz MM, et al. . The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004;65:521&#x2013;30. 10.1111/j.1523-1755.2004.00443.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-1755.2004.00443.x</ArticleId><ArticleId IdType="pubmed">14717922</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Iba&#xf1;ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol
2002;29:288&#x2013;91. Available: https://www.jrheum.org/content/29/2/288</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Genovese M, Engle E, et al. . Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 1991;34:937&#x2013;44. 10.1002/art.1780340802</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780340802</ArticleId><ArticleId IdType="pubmed">1859487</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang MH, Socher SA, Larson MG, et al. . Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107&#x2013;18. 10.1002/anr.1780320909</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anr.1780320909</ArticleId><ArticleId IdType="pubmed">2775320</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Y, Higgs BW, Morehouse C, et al. . Development of potential pharmacodynamic and diagnostic markers for anti-IFN-&#x3b1; monoclonal antibody trials in systemic lupus erythematosus. Hum Genomics Proteomics 2009;2009:374312. 10.4061/2009/374312</Citation><ArticleIdList><ArticleId IdType="doi">10.4061/2009/374312</ArticleId><ArticleId IdType="pmc">PMC2950308</ArticleId><ArticleId IdType="pubmed">20948567</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Y, Higgs BW, Richman L, et al. . Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFN&#x3b1; antibody, in systemic lupus erythematosus. Arthritis Res Ther 2010;12 (Suppl 1):S6. 10.1186/ar2887</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar2887</ArticleId><ArticleId IdType="pmc">PMC2991779</ArticleId><ArticleId IdType="pubmed">20392292</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghebreyesus TA. WHO director-general&#x2019;s opening remarks at the media briefing on COVID-19 - 11 March 2020. 2020. Available: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 [Accessed 08 Mar 2022].</Citation></Reference><Reference><Citation>Gorriz JL, Martinez-Castelao A. Proteinuria: detection and role in native renal disease progression. Transplant Rev (Orlando) 2012;26:3&#x2013;13. 10.1016/j.trre.2011.10.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trre.2011.10.002</ArticleId><ArticleId IdType="pubmed">22137726</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostopoulou M, Fanouriakis A, Cheema K, et al. . Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations. RMD Open 2020;6:e001263. 10.1136/rmdopen-2020-001263</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2020-001263</ArticleId><ArticleId IdType="pmc">PMC7425195</ArticleId><ArticleId IdType="pubmed">32699043</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugolini-Lopes MR, Seguro LPC, Castro MXF, et al. . Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis? Lupus Sci Med 2017;4:e000213. 10.1136/lupus-2017-000213</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2017-000213</ArticleId><ArticleId IdType="pmc">PMC5724342</ArticleId><ArticleId IdType="pubmed">29238603</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackay M, Dall&#x2019;Era M, Fishbein J, et al. . Establishing surrogate kidney end points for lupus nephritis clinical trials: development and validation of a novel approach to predict future kidney outcomes. Arthritis Rheumatol 2019;71:411&#x2013;9. 10.1002/art.40724</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40724</ArticleId><ArticleId IdType="pubmed">30225865</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YE, Korbet SM, Katz RS, et al. . Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 2008;3:46&#x2013;53. 10.2215/CJN.03280807</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.03280807</ArticleId><ArticleId IdType="pmc">PMC2390978</ArticleId><ArticleId IdType="pubmed">18003764</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson JE, Fu Q, Ji B, et al. . Renal remission status and longterm renal survival in patients with lupus nephritis: a retrospective cohort analysis. J Rheumatol 2018;45:671&#x2013;7. 10.3899/jrheum.161554</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.161554</ArticleId><ArticleId IdType="pmc">PMC5932209</ArticleId><ArticleId IdType="pubmed">29496892</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichinose K, Kitamura M, Sato S, et al. . Factors predictive of long-term mortality in lupus nephritis: a multicenter retrospective study of a Japanese cohort. Lupus 2019;28:295&#x2013;303. 10.1177/0961203319826690</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319826690</ArticleId><ArticleId IdType="pubmed">30700214</ArticleId></ArticleIdList></Reference><Reference><Citation>Corapi KM, Dooley MA, Pendergraft III WF. Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials. Arthritis Res Ther 2015;17:110. 10.1186/s13075-015-0621-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-015-0621-6</ArticleId><ArticleId IdType="pmc">PMC4411763</ArticleId><ArticleId IdType="pubmed">25927414</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders H-J, Jayne DRW, Rovin BH. Hurdles to the introduction of new therapies for immune-mediated kidney diseases. Nat Rev Nephrol 2016;12:205&#x2013;16. 10.1038/nrneph.2015.206</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2015.206</ArticleId><ArticleId IdType="pubmed">26804020</ArticleId></ArticleIdList></Reference><Reference><Citation>Houssiau FA, Vasconcelos C, D&#x2019;Cruz D, et al. . Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004;50:3934&#x2013;40. 10.1002/art.20666</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20666</ArticleId><ArticleId IdType="pubmed">15593207</ArticleId></ArticleIdList></Reference><Reference><Citation>Tummala R, Abreu G, Pineda L, et al. . Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Sci Med 2021;8:e000464. 10.1136/lupus-2020-000464</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000464</ArticleId><ArticleId IdType="pmc">PMC7893670</ArticleId><ArticleId IdType="pubmed">33597205</ArticleId></ArticleIdList></Reference><Reference><Citation>Daleboudt GMN, Broadbent E, McQueen F, et al. . Intentional and unintentional treatment nonadherence in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2011;63:342&#x2013;50. 10.1002/acr.20411</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.20411</ArticleId><ArticleId IdType="pubmed">21120967</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Gonzalez A, Richardson M, Garcia Popa-Lisseanu M, et al. . Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol 2008;27:883&#x2013;9. 10.1007/s10067-007-0816-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-007-0816-6</ArticleId><ArticleId IdType="pubmed">18185905</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson A, Aranow C, Mackay M. Lupus nephritis: challenges and progress. Curr Opin Rheumatol 2019;31:682&#x2013;8. 10.1097/BOR.0000000000000642</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000642</ArticleId><ArticleId IdType="pmc">PMC6812494</ArticleId><ArticleId IdType="pubmed">31389814</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>